BioNxt Solutions Advances Patent Protection for MS Treatment

BioNxt Solutions Inc., a bioscience company, has announced developments in its global patent portfolio. The European Patent Office and the Eurasian Patent Organization have accepted the core claims of BioNxt’s patent for a sublingual Cladribine-based formulation, anticipating full grants soon. This development reinforces BioNxt’s intellectual property strategy for its drug delivery technologies targeting autoimmune neurological diseases.

The European Patent Office issued an Office Action indicating that the patent application meets key criteria, requiring only minor amendments. Similarly, the Eurasian Patent Organization accepted the application after minor modifications. These crucial steps pave the way for formal patent grants across multiple key jurisdictions.

BioNxt’s ongoing patent strategy is part of its broader commercialization and regulatory plan, enhancing global protection for its innovative treatment of relapsing-remitting multiple sclerosis. This patent covers the sublingual delivery system, optimizing drug absorption and improving patient compliance.